Clinical trials: Diabetic Nephropathy Type 2
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals
Diabetic Kidney Disease, Chronic Kidney Diseases
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- NCT05198284
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Chronic Kidney Diseases, Diabetic Kidney Disease
Real World Evidence Clinical Utility Study of KidneyIntelX
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
- Trial name
- NCT04802395
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathies
An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
Diabetic kidney disease (nephropathy) develops in nearly 40% of patients with type 2 diabetes mellitus. Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys due to uncontrolled blood sugar levels…
- Trial name
- IDEAL-2 (NCT03216564)
- Testing
- Calcitriol
- Where
- Qatar
- Volunteers
- 320 people
- Sponsor
- Hamad Medical Corporation
Heart Failure, Chronic Kidney Disease
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of…
- Trial name
- MIRACLE (NCT04595370)
- Testing
- AZD9977, Dapagliflozin
- Where
- 156 sites in United States, Belgium and 20 more
- Volunteers
- 153 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- NCT00913393
- Testing
- FG-3019
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kyntra Bio
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
- Trial name
- NCT01053936
- Testing
- Bardoxolone methyl (amorphous dispersion)
- Where
- 26 sites in United States
- Volunteers
- 129 people
- Sponsor
- Biogen
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of treatment with CCX140-B in subjects with diabetic nephropathy.
- Trial name
- NCT01447147
- Testing
- CCX140-B
- Where
- 83 sites in Belgium, Czechia and 4 more
- Volunteers
- 332 people
- Sponsor
- Amgen
Diabetic Nephropathy
Effect of Sulodexide in Overt Diabetic Nephropathy
The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.
- Trial name
- NCT00130312
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 968 people
- Sponsor
- Keryx Biopharmaceuticals
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Nephropathy, Diabetic
- Trial name
- NCT04534439
- Testing
- APX-115
- Where
- 16 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 140 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetic Kidney Disease
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic…
- Trial name
- NCT06489340
- Testing
- 2HPβCD
- Where
- United States
- Sponsor
- ZyVersa Therapeutics, Inc.
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication…
- Trial name
- NCT01440257
- Testing
- CCX140-B
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amgen
Diabetic Nephropathies
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
- Trial name
- NCT05718375
- Testing
- CU01-1001
- Where
- 24 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.
- Trial name
- NCT01869881
- Testing
- Anplag(Sarpogrelate)
- Where
- South Korea
- Volunteers
- 151 people
- Sponsor
- Yuhan Corporation
Diabetes, Magnetic Resonance Imaging
Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients
This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic…
- Trial name
- NCT06051565
- Testing
- Polysaccharide superparamagnetic iron oxide injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company